Recently, Kuno et al. [7], compared the efficacy and safety of nine antithrombotic strategies, including combinations of vitamin K antagonist with dual antiplatelet therapy or a P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor), and combinations of DOAC (apixaban, dabigatran, rivaroxaban, and edoxaban) with dual antiplatelet therapy or a P2Y12 inhibitor, in patients with AF undergoing coronary interventions. The gene discussed is P2RY12; the disease is atrial fibrillation.